OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on October 30, 2024. The filing serves to announce the company's participation in the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy, scheduled from October 30 to November 2, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event announcement and does not contain financial statements or performance metrics.
Material Changes and Operational Updates
- Conference Participation: Management will present at the International Tear Film & Ocular Surface Society Conference.
- Dry Eye Disease: The company will discuss trial results for its dry eye disease program during one-on-one meetings.
- Phase 2 Trial Initiation: The company announced the recent opening of a Phase 2 trial for OK-101 to treat Neuropathic Corneal Pain at Tufts Medical Center in Boston, Massachusetts.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, quantitative outlook, or a discussion of risks and contingencies. The primary focus is on the upcoming clinical trial discussions and the initiation of the new Phase 2 study.
Key Facts for Investor Verification
- Verify the specific details of the dry eye disease trial results to be discussed at the Venice conference.
- Confirm the enrollment status and design of the newly opened Phase 2 trial for OK-101 at Tufts Medical Center.
- Review the attached Exhibit 99.1 for the full text of the announcement, as the Form 6-K itself is a cover document.